TT-00434 is an irreversible, highly selective inhibitor of FGFR1, 2, and 3 with potent preclinical activity against tumors harboring FGFR aberrations.

C4 Therapeutics, Inc., a company developing targeted protein degradation drugs, has announced early results from its Phase 1/2 trial's initial dose-escalation stage. The trial evaluates CFT7455, a unique MonoDAC™ agent targeting IKZF1/3 proteins, for treating multiple myeloma and non-Hodgkin lymphomas.

Oligonucleotide drugs are a class of medications that are composed of short, synthetic pieces of DNA or RNA known as oligonucleotides.

Shattuck Labs Reveals Promising Early Results from Continual Phase 1 A/B Clinical Study of SL-172154 Combined with Azacitidine in Newly Diagnosed Advanced Myelodysplastic Conditions (HR-MDS) and TP53 Mutation-Positive Acute Myeloid Leukemia Patients.

On 2 Dec 2023, the updated results of these two studies with extended follow-up were presented in 2023 ESMO_ASIA.

Plexium has begun dosing in a Phase 1 trial for its oral drug PLX-4545, a molecular glue degrader targeting the previously "undruggable" transcription factor IKZF2, also known as Helios.

The search for more sensitive and safer specific RET inhibitors to provide precision treatment and personalized treatment for cancer patients will be the main research direction in the future.

The European Commission has sanctioned Blueprint Medicines' drug AYVAKYT® (avapritinib) as the exclusive therapeutic option for indolent systemic mastocytosis.

On 3 Dec 2023, the latest clinical result of MCLA-129, an anti-EGFR/c-MET bispecific antibody, for the treatment on non-small cell lung cancer was reported in 2023 ESMO_ASIA.

Clover Biopharmaceuticals, Ltd. has announced the enrollment of the first group of participants for its Phase I clinical trial evaluating the SCB-1019 vaccine against Respiratory Syncytial Virus (RSV).

The primary reporter is the first person who provides individual safety information, regardless of whether the reporter is a medical professional.

The FDA is reviewing the updated New Drug Application (NDA) for TransCon PTH (also known as Palopegteriparatide) meant for the treatment of hypoparathyroidism in adults.